Treatment of leg ulcers with platelet-derived wound healing factor (PDWHFS) in a patient with beta thalassaemia intermedia [2]

British Journal of Haematology

Volumn 112, Issue 2, 2001, Pages 528-529

  Josifova, Dragana ^a,b   Gatt, Gabriella ^b   Aquilina, Alex ^c   Serafimov V, Viktor ^a   Vella, Adrian ^d   Felice, Alex E ^a,b  

^a St Luke's Hospital   (United States)

^b UNIVERSITY OF MALTA   (Malta)

^c National Blood Transfusion Centre   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Beta thalassaemia; Leg ulcers; Platelet derived growth factor

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; WOUND HEALING PROMOTING AGENT; CT 102 ACTIVATED PLATELET SUPERNATANT; CT-102 ACTIVATED PLATELET SUPERNATANT; GROWTH PROMOTOR;

ADULT; BETA THALASSEMIA; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; LEG ULCER; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCER HEALING; DRUG MIXTURE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; BETA-THALASSEMIA; COMPLEX MIXTURES; FEMALE; GROWTH SUBSTANCES; HUMANS; LEG ULCER;

EID: 0035114174     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Growth factors in wound healing: The next great innovation?
2. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers
3. Becaplermin gel in the treatment of pressure ulcers: A phase II randomised, double-blind, placebo-controlled study
4. The biology of platelet derived growth factor
5. The thalassaemia syndromes